Skip to main content
Premium Trial:

Request an Annual Quote

Affitech Licenses Phage Display Tech to Dyax

NEW YORK, Dec. 21 (GenomeWeb News) - Oslo-based Affitech announced recently that it has licensed its phage display technology to Dyax, of Cambridge, Mass.


Dyax is the first licensee of Affitech's core patent portfolio, which covers phagemid display of antibodies and antibody fragments, Affitech said. Specifically, the worldwide patent covers the use of full-length pIII phage protein as a scaffold in a phagemid vector.


Affitech obtained the exclusive worldwide rights to the patent from the DKFZ (German Cancer Research Center) in Heidelberg, Germany.


Financial terms of the deal were not disclosed.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.